Alliance for Clinical Trials in Oncology shared on LinkedIn:
“For patients with early-stage triple-negative breast cancer who achieve a pathologic complete response after chemotherapy and pembrolizumab, what’s next? Should treatment continue – or is monitoring enough?
The Alliance A012103 trial, led by Dr. Sara Tolaney at Dana-Farber, and is a phase III study designed to compare:
- Continuing pembrolizumab after surgery
- Monitoring only (‘watch and wait’)
Why does this matter? If monitoring proves just as effective, patients could avoid unnecessary treatment, reduce side effects, and improve quality of life – while still maintaining excellent outcomes.
This research could reshape how we approach care for TNBC patients who respond well to initial therapy.
Learn more or share with your network.”
